Ibustrin (Indobufen)

Indobufen reversibly blocks platelet cyclooxygenase, which lowers the production of thromboxane A2, a key molecule that promotes platelet aggregation. By reducing thromboxane A2 levels, the drug diminishes platelet activation and helps prevent the formation of arterial clots.

The specific dose of Ibustrin is determined by the prescribing clinician based on the patient’s medical condition, risk factors, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety data for indobufen in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers must evaluate each case individually and discuss potential risks with the patient.

To request Ibustrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibustrin (indobufen) is a reversible cyclooxygenase inhibitor, whereas agents like aspirin irreversibly inhibit the same enzyme. Compared with clopidogrel, which blocks the P2Y12 receptor, indobufen has a different mechanism and may have a distinct bleeding profile. Choice of therapy depends on clinical indication, patient tolerance and physician judgment.

Ibustrin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ibustrin is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless directed otherwise by a healthcare professional. Administration timing (e.g., with or without food) follows the prescriber’s guidance.

The most serious risks include severe bleeding events such as gastrointestinal hemorrhage, intracranial bleeding, and allergic reactions that may lead to anaphylaxis. Patients should be educated to recognize signs of major bleeding and seek immediate medical attention if they occur.

Ibustrin is contraindicated in individuals with active major bleeding, known hypersensitivity to indobufen or any component of the formulation, and in patients who are concurrently using multiple antiplatelet or anticoagulant agents without clear clinical justification. Clinicians should assess each patient’s medical history before prescribing.